Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
366.69
-4.68 (-1.26%)
At close: Jan 7, 2026, 4:00 PM EST
371.11
+4.42 (1.21%)
Pre-market: Jan 8, 2026, 5:01 AM EST
Elevance Health Stock Forecast
Stock Price Forecast
The 16 analysts that cover Elevance Health stock have a consensus rating of "Buy" and an average price target of $390, which forecasts a 6.36% increase in the stock price over the next year. The lowest target is $297 and the highest is $485.
Price Target: $390 (+6.36%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Elevance Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 8 | 8 | 6 | 6 | 6 | 6 |
| Hold | 3 | 3 | 6 | 6 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 16 | 16 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $403 → $424 | Buy | Maintains | $403 → $424 | +15.63% | Jan 7, 2026 |
| Barclays | Barclays | Buy Maintains $385 → $404 | Buy | Maintains | $385 → $404 | +10.17% | Jan 5, 2026 |
| Deutsche Bank | Deutsche Bank | Strong Buy → Hold Downgrades $332 → $320 | Strong Buy → Hold | Downgrades | $332 → $320 | -12.73% | Dec 19, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $359 → $352 | Hold | Maintains | $359 → $352 | -4.01% | Dec 18, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $380 → $400 | Strong Buy | Maintains | $380 → $400 | +9.08% | Nov 26, 2025 |
Financial Forecast
Revenue This Year
200.18B
from 176.81B
Increased by 13.22%
Revenue Next Year
207.17B
from 200.18B
Increased by 3.49%
EPS This Year
30.29
from 25.68
Increased by 17.94%
EPS Next Year
27.31
from 30.29
Decreased by -9.83%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 211.1B | 224.9B | |||
| Avg | 200.2B | 207.2B | |||
| Low | 192.7B | 193.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.4% | 12.3% | |||
| Avg | 13.2% | 3.5% | |||
| Low | 9.0% | -3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 31.68 | 31.03 | ||||
| Avg | 30.29 | 27.31 | ||||
| Low | 29.08 | 24.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 23.4% | 2.4% | ||||
| Avg | 17.9% | -9.8% | ||||
| Low | 13.2% | -20.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.